Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Eisai, Inc.
Scientific Title
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma.